http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Pfizer (PFE) Phase 3 PALLAS Trial of IBRANCE Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer Unlikely to Show Statistically Significant Improvement
-
Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE® (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer
-
Corning and Pfizer Announce Supply Agreement for Corning Valor® Glass Packaging
-
Corning and Pfizer Announce Supply Agreement for Corning Valor® Glass Packaging
-
ContraFect (CFRX) Announces Private Placement of Common Stock and Warrants to Pfizer
-
ContraFect Corporation Announces Private Placement of Common Stock and Warrants to Pfizer Inc.
-
Pfizer Inc. Recommends Rejection of Unsolicited Note Tender Offer by Huguenot Bond Liquidity, LLC
-
Pfizer Prices $4,000,000,000 Debt Offering
-
Pfizer (PFE) Reports New Phase 1b Results of Gene Therapy in Ambulatory Boys with DMD Support Advancement into Pivotal Phase 3 Study
-
Pfizer’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study
-
Pfizer (PFE) Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age
-
Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age
-
Save the Date: Pfizer Announces New Date of September 14, 2020 for Rescheduled Investor Day
-
New Data from 18 Approved and Investigational Pfizer Medicines to be Showcased at ASCO20 Virtual Scientific Program
-
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
-
Pfizer Invites Public to View and Listen to Webcast of May 15 Conference Call with Analysts to Review Duchenne Muscular Dystrophy (DMD) Data Presentation at ASGCT 2020 Annual Meeting
-
Pfizer (PFE), BioNTech (BNTX) Dose First Participants in U.S. as Part of Global COVID-19 mRNA Vaccine Development Program
-
Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program
-
Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program
-
New Data Suggest Burden of Group B Streptococcus (GBS) Infection in U.S. Adults Greater Than Previously Recognized
-
Pfizer (PFE), Valneva Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15
-
Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15
-
Pfizer (PFE), BioTech (BNTX) Report Complete Patient Dosing in First Cohort of Ph. 1/2 Trial of COVID-19 vaccine candidates in Germany
-
BioNTech and Pfizer announce completion of dosing for first cohort of Phase 1/2 trial of COVID-19 vaccine candidates in Germany
-
BioNTech and Pfizer announce completion of dosing for first cohort of Phase 1/2 trial of COVID-19 vaccine candidates in Germany
-
Pfizer Hosts Virtual-Only Annual Meeting of Shareholders
-
BioNTech and Pfizer announce regulatory approval from German authority Paul-Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine candidates
-
BioNTech and Pfizer announce regulatory approval from German authority Paul-Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine candidates
-
Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development
-
Pfizer Advances Battle Against COVID-19 on Multiple Fronts
-
Pfizer (PFE) and BioNTech (BNTX) Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development
-
Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development
-
Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development
-
Pfizer (PFE), EMD Serono Granted FDA Breakthrough Therapy Designation & Submit Application for BAVENCIO
-
EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO® for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
-
U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy
-
Pfizer to Hold Virtual-Only 2020 Annual Meeting of Shareholders
-
Pfizer and The Pfizer Foundation Donate $40 Million in Charitable Grants, Expand Product Access and Mobilize Colleagues to Combat COVID-19 Pandemic
-
Pfizer (PFE) Receives European Approval for Oncology Biosimilar, RUXIENCE
-
Pfizer Receives European Approval for Oncology Biosimilar, RUXIENCE™ (rituximab)
-
Pfizer (PFE) Reports Election of Susan Desmond-Hellmann to Board
-
Susan Desmond-Hellmann Elected to Pfizer’s Board of Directors
-
Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic
-
Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic
-
Pfizer Completes $1.25 Billion Sustainability Bond for Social and Environmental Impact
-
Mylan (MYL), Pfizer (PFE) Provide Update Regarding Proposed Combination of Mylan and Upjohn
-
Mylan and Pfizer Provide Update Regarding Proposed Combination of Mylan and Upjohn
-
Mylan and Pfizer Provide Update Regarding Proposed Combination of Mylan and Upjohn
-
Pfizer (PFE) Announces U.S. FDA Approves sNDA for Expanded Indication of EUCRISA Ointment, 2% in AD
-
U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of EUCRISA® (Crisaborole) Ointment, 2%, in Children as Young as 3 Months of Age With Mild-to-Moderate Atopic Dermati

